These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9602985)

  • 1. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome.
    Mangel AW; Hahn BA; Heath AT; Northcutt AR; Kong S; Dukes GE; McSorley D
    J Int Med Res; 1998; 26(2):76-81. PubMed ID: 9602985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
    Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
    Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
    Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
    Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
    Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
    Maxton DG; Morris J; Whorwell PJ
    Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
    Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
    Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
    Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
    Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
    George AM; Meyers NL; Hickling RI
    Aliment Pharmacol Ther; 2008 May; 27(9):830-7. PubMed ID: 18284648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
    Mangel AW; Chaturvedi P
    Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
    Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
    Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial.
    Mitchell SA; Mee AS; Smith GD; Palmer KR; Chapman RW
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1187-95. PubMed ID: 12030962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
    Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
    Tuteja AK; Fang JC; Al-Suqi M; Stoddard GJ; Hale DC
    Scand J Gastroenterol; 2012 Oct; 47(10):1159-64. PubMed ID: 22783919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
    Clavé P; Acalovschi M; Triantafillidis JK; Uspensky YP; Kalayci C; Shee V; Tack J;
    Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.